Literature DB >> 837650

Theophylline kinetics in acute pulmonary edema.

K M Piafsky, D S Sitar, R E Rangno, R I Ogilvie.   

Abstract

Nine patients with acute cardiogenic pulmonary edema were given theophylline intravenously, and its disposition was observed over the next 24 hr. Compared to that in 19 normal subjects, these patients had prolonged plasma half-lifes (mean, 22.9 from 6.7 hr) and decreased plasma clearances of theophylline (mean, 0.041 from 0.062 L [kg-1] hr-1). The intersubject variation in these parameters was 20-fold in patients with pulmonary edema and 4-fold in normal subjects. Since the peak plasma concentrations attained and the apparent volumes of distribution were not different in the two groups, a suitable initial dose can be calculated. A loading dose of 4.5 to 5 mg/kg theophylline (6 mg/kg aminophylline) given over 20 min appears safe. Because of the great variability in the plasma clearance of this drug in patients with heart failure, plasma concentrations and toxicity would be unpredictable after repeated doses or constant infusions.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837650     DOI: 10.1002/cpt1977213310

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  43 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

4.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 5.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 6.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 7.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Theophylline elimination in congestive heart failure.

Authors:  H D Kuntz; H Straub; B May
Journal:  Klin Wochenschr       Date:  1983-11-02

Review 9.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

10.  Impaired theophylline clearance in patients with cor pulmonale.

Authors:  N Vicuna; J L McNay; T M Ludden; H Schwertner
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.